Research Paper Volume 13, Issue 11 pp 15164—15192
Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma
Figure 4. Validation of the lncRNA signature for genomic instability used to predict outcomes in the testing and TCGA set. (A) Validation of overall survival in low- or high-risk patients predicted by pooling GILncSig with Kaplan-Meier estimates. (B) Time-dependent ROC curves of GILncSig at 1, 2 and 3 years in the testing group. (C) Verification of LncRNA expression patterns, the profile of somatic mutations and UBQLN4 expression in patients in low- and high-risk groups. (D–E) Box plots for the distribution of somatic mutations and UBQLN4 expression in high- and low-risk groups of patients. (F–J) Verification of the above results using the TCGA set.